Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

Core Insights - Annovis Bio, Inc. has fully activated all 84 clinical sites for its pivotal Phase 3 study in early Alzheimer's disease (AD), with patient enrollment and treatment underway [1][2] - The first group of participants has reached the 6-month treatment milestone, keeping the study on track for data readout in the second half of 2026 [1][2] - The Phase 3 trial aims to enroll a total of 760 patients with early AD and biomarker-confirmed amyloid pathology, featuring a dual design for evaluating symptomatic efficacy and potential disease-modifying response [2] Enrollment and Progress - The trial is currently 25% complete, demonstrating strong execution in patient enrollment and progression through the protocol [2][3] - The dedication of the team, site partners, and patient engagement has contributed to the momentum of the trial [3] Company Overview - Annovis is headquartered in Malvern, Pennsylvania, focusing on innovative therapies for neurodegenerative diseases such as AD and Parkinson's disease (PD) [4] - The company is committed to improving patient outcomes and quality of life through its drug development efforts [4]